Cadila Healthcare has entered into an asset purchase agreement to sell its right, title and interest in ZYPITAMAG (Pitavastatin), along with applicable registrations and intangible assets relating to ZYPITAMAG for USA and Canada markets to Medicure Inc., a cardiovascular pharmaceutical company. Medicure had previously acquired US marketing rights with a profit-sharing arrangement with Cadila.
With this acquisition, Medicure retains all profits, with full control of marketing and pricing negotiation for USA and Canada markets. Under terms of the agreement, the company will receive an upfront payment of $5 million and $2 million in deferred payments to be made over the next four years, contingent payments on achievement of sales milestones and royalties on net sales.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: